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Abstract
Background: Recent findings indicate that certain classes of hypnotics that target GABAA receptors impair sleep-dependent
brain plasticity. However, the effects of hypnotics acting at monoamine receptors (e.g., the antidepressant trazodone) on
this process are unknown. We therefore assessed the effects of commonly-prescribed medications for the treatment of
insomnia (trazodone and the non-benzodiazepine GABAA receptor agonists zaleplon and eszopiclone) in a canonical model
of sleep-dependent, in vivo synaptic plasticity in the primary visual cortex (V1) known as ocular dominance plasticity.
Methodology/Principal Findings: After a 6-h baseline period of sleep/wake polysomnographic recording, cats underwent
6 h of continuous waking combined with monocular deprivation (MD) to trigger synaptic remodeling. Cats subsequently
received an i.p. injection of either vehicle, trazodone (10 mg/kg), zaleplon (10 mg/kg), or eszopiclone (1–10 mg/kg), and
were allowed an 8-h period of post-MD sleep before ocular dominance plasticity was assessed. We found that while
zaleplon and eszopiclone had profound effects on sleeping cortical electroencephalographic (EEG) activity, only trazodone
(which did not alter EEG activity) significantly impaired sleep-dependent consolidation of ocular dominance plasticity. This
was associated with deficits in both the normal depression of V1 neuronal responses to deprived-eye stimulation, and
potentiation of responses to non-deprived eye stimulation, which accompany ocular dominance plasticity.
Conclusions/Significance: Taken together, our data suggest that the monoamine receptors targeted by trazodone play an
important role in sleep-dependent consolidation of synaptic plasticity. They also demonstrate that changes in sleep
architecture are not necessarily reliable predictors of how hypnotics affect sleep-dependent neural functions.
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Introduction
Behavioral findings in animals and humans suggest an
important role for sleep in the consolidation of learning and
memory; however, much less is known about how sleep affects the
synaptic and brain system-level changes that underlie these
processes [1,2]. Certain hypnotic drugs can cause anterograde
amnesia during wakefulness [3,4], and may inhibit synaptic
plasticity in vitro [5,6], but it is unclear how they affect sleep-
dependent consolidation processes and in vivo synaptic plasticity.
Importantly, the most commonly-prescribed hypnotics target
diverse neurotransmitter systems that may interfere with plastic
processes that occur during sleep.
Ocular dominance plasticity in the primary visual cortex (V1) is
triggered by monocular deprivation (MD) during a critical
developmental window. We have previously shown that the effects
of MD are consolidated by subsequent sleep, but inhibited by sleep
deprivation, or when sleep is combined with the non-benzodiaz-
epine hypnotic zolpidem [7–11]. This suggests that certain classes
of hypnotics targeting the GABAA receptor impair synaptic
remodeling during sleep. What has not been investigated,
however, are the effects of other ‘‘z’’ hypnotics (e.g., zaleplon,
[es]zopiclone) [12,13] and the atypical, but commonly prescribed
hypnotic trazodone on sleep-dependent brain plasticity.
In contrast to benzodiazepine and non-benzodiazepine hypnot-
ics, the sedating antidepressant trazodone acts as both a weak
serotonin (5-HT) reuptake inhibitor and as an antagonist at 5-HT2A
and 5-HT2C, a1-adrenergic, and histamine H1 receptors [14,15].
Because intracellular signaling pathways regulated by monoamin-
ergic neurotransmission have been shown to modulate diverse forms
of in vivo synaptic plasticity [16,17], it is possible that antagonizing
monoaminergic signaling with trazodone during sleep inhibits
plasticity. To investigate this possibility, we compared the effects of
trazodone (TRA), zaleplon (ZAL) and eszopiclone (ESZ) on a classic
in vivo form of cortical plasticity that is consolidated by sleep.
Results
Effects of hypnotics on post-MD sleep architecture and
EEG activity
Polysomnography showed that the three hypnotics had similar
effects on overall sleep/wake amounts and durations (Fig. 1). All
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three drugs led to significant decreases in rapid eye movement
(REM) sleep, and concomitant increases in non-REM (NREM)
sleep, relative to vehicle (VEH; Fig. 1C; effects of treatment on %
of total recording time for the three vigilance states: F=6.3,
p=0.004 for NREM; F=7.1, p=0.003 for REM; H=12.5,
p=0.006 for wake, one-way ANOVA). Similar effects were seen
for mean REM sleep bout durations in the post-MD period
(Fig. 1C), which were significantly reduced in all three hypnotic-
treated groups relative to VEH (effects of treatment on REM sleep
and wake bout durations: F=6.2, p=0.005, and H=10.5,
p=0.015, respectively). Latencies to the first REM sleep episode
also increased in all three hypnotic-treated groups, but this was
only significant in the ESZ and ZAL-treated cats when compared
with VEH cats (latency [mean6SEM] = 25.664.9 min for VEH,
50614.6 min for TRA, 79.669.3 min for ZAL*, 104.3618.5 min
for ESZ*; F=6.5, p=0.004, one-way ANOVA; * indicates
p,0.05, Holm-Sidak post hoc test vs. VEH). As described previously
for other hypnotic agents [11], we also occasionally observed a
state that appeared intermediate between waking and NREM
sleep - described as ‘‘NREM-drowsy’’ (ND) - in a subset of ESZ-
and ZAL-treated animals (ESZ, n=2; ZAL, n=1). However, the
amount of ND in these animals was very low across the 8-h post-
MD sleep period (0.7%60.4% and 2.1% of total recording time,
respectively; data not shown). Because of the similarity of ND to
NREM sleep, ND periods were included in calculations of NREM
state amounts and bout durations (but were excluded from NREM
EEG analysis), as described previously [11].
Of the three drugs tested, TRA led to the most substantial and
persistent increases in NREM sleep time relative to VEH, which
continued throughout the 8-h post-MD sleep period (Fig. S1,
Table S1; TRA vs. VEH: p,0.05 at 2–4 h and 4–6 h post-
injection, Holm-Sidak post hoc test; ZAL and ESZ vs. VEH: N.S. at
2–4 h and 4–6 h post-injection).
The three hypnotics differed more in their effects on sleeping
EEG activity. As previously reported with the benzodiazepine
triazolam [11], both ZAL and ESZ led to significant increases over
VEH in EEG power spectra in the sigma, beta, and gamma
frequency ranges, during both REM and NREM sleep (Fig. 2;
Table S2). These changes in EEG activity persisted throughout
the post-MD recording period. In contrast, TRA treatment
produced no significant changes in EEG power spectra relative
to VEH in either sleep state.
Effects of hypnotics on sleep-dependent cortical
plasticity
Single-unit recordings within the primary visual cortex (V1)
showed marked differences in cortical plasticity between the
treatment groups. In agreement with an earlier report [11],
single-unit recording revealed that animals treated with VEH after
the 6-h monocular deprivation (MD) period showed normal ocular
dominance plasticity after an 8-h period of post-MD sleep (Fig. 3A).
While this plasticity was not significantly reduced by ZAL or ESZ
treatment, it was inhibited in animals treated with TRA. This
inhibition was evident in the ocular dominance distribution of
neurons recorded from TRA-treated cats (Fig. 3A), and also from
scalar measures of ocular dominance (Fig. 3B). For example, the
overall change seen in SIs in VEH-treated animals (vs. that seen in
‘‘Normal’’ cats [with unmanipulated binocular vision and sleep])
was reduced by 46% when animals were treated with TRA.
Moreover, only VEH-, ZAL-, and ESZ-treated cats showed
significantly greater SIs than Normal cats (F=6.3, p= 0.001, one-
way ANOVA; p,0.05, Holm-Sidak test vs. Normal; Fig. 3B).
Similar effects of TRA were seen for single-unit non-deprived eye
bias indices (NBIs; NBIboth hemispheres: H=18.8, p,0.001,
NBIright hemisphere: F=9.6, p,0.001; NBIleft hemisphere: N.S., one-
way ANOVA; Fig. 3B). The overall increase in NBI values in
VEH-treated cats was significantly reduced in neurons recorded
from TRA-treated cats (by 50%; p,0.05, Dunn’s post hoc test vs.
VEH). Monocularity indices (MIs) were similarly affected, with an
overall reduction of 51% in TRA-treated animals. Again, when
Normal data were compared with the four treatment groups, VEH-,
Figure 1. Experimental design and hypnotic effects on post-
MD sleep. Schematized experimental design is shown in A. All animals
underwent polysomnographic recording over a 6-h baseline period
prior to a 6-h period of waking combined with MD. After the MD period,
cats received an i.p. injection of either hypnotic or vehicle (time
indicated by arrowhead) and were then allowed and 8-h period of ad lib
sleep in total darkness, after which ocular dominance (OD) was
assessed. Representative post-MD hypnograms (B) from animals in
each of the treatment groups show transitions between wake (W), REM
(R), and NREM (N) sleep. VEH= vehicle (n= 6), ZAL = zaleplon (n=5),
ESZ= eszopiclone (n= 6), TRA= trazodone (n= 5). Bar graphs in C show
mean (6SEM) % of total recording time (%TRT; left) spent in NREM
(black bars), REM (light gray), and wake (dark gray), and mean (6SEM)
bout duration for each vigilance state (right) during the post-MD
period. * indicates p,0.05, # indicates p,0.001, vs. VEH, post hoc
Holm-Sidak or Dunn’s test.
doi:10.1371/journal.pone.0006078.g001
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ZAL-, and ESZ-treated cats showed significantly greater single-unit
MIs (F=8.5, p,0.001, one-way ANOVA; p,0.01, Holm-Sidak
test vs. Normal), while TRA-treated cats did not (Fig. 3B).
Similar trends were observed using intrinsic signal imaging as a
second measure of ocular dominance plasticity (with lower overall
values in the TRA group; Text S1, Fig. S2), but these did reach
significance when the VEH- and hypnotic-treated groups were
compared directly (one-way ANOVA, N.S.). However, scalar
measures of plasticity were all decreased in TRA-treated V1 (by
13%, 13%, and 58% for SI, NBI, and MI, respectively) compared
with changes in VEH-treated animals. When data from the four
treatment groups were compared with data from Normal cats (Fig.
S2C), VEH-, ZAL-, and ESZ-treated cats showed significantly
greater intrinsic signal MIs (H=18.6, p,0.001, Kruskall-Wallis
one-way ANOVA; p,0.05, Dunn’s test vs. Normal) - indicative of
greater plasticity, while TRA-treated cats did not.
Effects of hypnotics on response properties of V1
neurons
We analyzed additional single-unit response properties in
neurons from the main treatment groups to further define changes
in non-deprived eye (NDE) and deprived eye (DE) pathways.
These included comparisons of normalized spike rates at the
preferred stimulus orientation for both eyes (Fig. 4A; see
MATERIALS AND METHODS for description of normaliza-
tion procedures) and assessments of orientation selectivity (OSI45,
Fig. 4B and OSI90, data not shown) using previously published
methods [7,18,19]. The proportion of visually-responsive neurons
Figure 2. Drug effects on EEG power spectra during post-MD sleep. Data represent NREM and REM EEGs (expressed as a % of corresponding
baseline values) averaged in 2-h bins (6SEMs) in the post-MD period. Analysis of variance for EEG power densities during post-MD sleep indicated
significant effects of treatment group, and significant group6frequency interactions, throughout the post-MD period (two-way ANOVA, results
shown in Table S2). Significant changes in EEG power in hypnotic-treated animals (compared to VEH; Holm-Sidak test vs. VEH, p,0.05) are
represented by color-coded bars on the bottom of the graphs.
doi:10.1371/journal.pone.0006078.g002
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(showing a greater mean firing rate response for oriented gratings
than for blank screen presentations) was similar between the main
groups (Normal: 99.4%, VEH: 99.9%, ZAL: 99.2%, ESZ: 98.9%,
TRA: 99.6%). We found that MD and subsequent sleep altered
visual response properties in both NDE and DE pathways,
consistent with prior reports of MD effects [20,21]. For example,
in VEH animals there were significant increases in peak firing rate
and orientation selectivity of responses to stimuli presented to the
NDE (relative to left eye responses in Normal cats; p,0.000001
and p,0.05, respectively, K-S test; Fig. 4A–B), and reductions in
these parameters for DE responses (relative to Normal right eye
responses; p,0.000001 and p,0.0005, respectively, K-S test).
In general, ESZ and ZAL tended to enhance changes in NDE
and DE pathways, while TRA tended to inhibit these changes. For
example, increased NDE peak firing and orientation selectivity
(relative to Normal left eye responses) was observed in neurons from
all hypnotic-treated animals (firing [Fig. 4A]: p,0.000001 for all
groups vs. Normal, K-S test; OSI45 [Fig. 4B]: p,0.0005,
p,0.000001, and p,0.05 for ZAL, ESZ, and TRA vs. Normal).
However, relative to VEH, ZAL further increased NDE peak firing
rates (p,0.0005 vs. VEH, K-S test), and ZAL and ESZ both further
enhanced NDE OSI45 (p,0.05 and p,0.000001 vs. VEH,
respectively). In contrast, TRA led to slightly (but not significantly,
p=0.09) reduced NDE peak firing rates relative to VEH, and
reduced NDEOSI45 (p,0.05 vs. VEH). Similar effects of hypnotics
on DE responses were observed. Neurons from all three treatment
groups showed reduced DE peak firing rates and OSI45 (relative to
right eye responses from Normal V1 neurons; firing [Fig. 4A]:
p,0.000001, p,0.000001, and p,0.05 for ZAL, ESZ, and TRA;
OSI45 [Fig. 4B]: p,0.000001, p,0.000001, and p,0.001 for
ZAL, ESZ, and TRA). However, relative to VEH, ZAL further
decreased DE peak firing rates (p,0.05), while TRA impaired DE
response depression (p,0.000001 vs. VEH, K-S test). All three
drugs also increased DE OSI45 relative to VEH (p,0.0005,
p,0.000001, and p,0.005 for ZAL, ESZ, and TRA vs. VEH).
Assessment of non-specific effects of trazodone on the
visual cortex
Because TRA was the only compound to significantly affect
ocular dominance plasticity, we conducted two additional sets of
control experiments to rule out non-specific effects of TRA on
visual cortical neurons (see Text S1 for details). In the first set of
Figure 3. Trazodone impairs sleep-dependent cortical plasticity. Ocular dominance histograms for single neurons (A) recorded from both
hemispheres (TOTAL) and in hemispheres ipsilateral (IPSI) and contralateral (CONTRA) to the deprived eye (DE) are shown for each of the treatment
groups. Ocular dominance scores were ranked on a 7-point scale as described previously [8]. n= number of neurons recorded in each condition.
Quantitative measurements of ocular dominance for both hemispheres are shown in B. One-way ANOVA showed a significant effect of treatment for
shift indices (SIs), non-deprived eye bias indices (NBIs), and monocularity indices (MIs). For NBIs, * indicates p,0.05, Dunn’s and Holm-Sidak test vs.
VEH for combined-hemisphere data and right-hemisphere data, respectively. For all measures, # indicates p,0.05, Dunn’s or Holm-Sidak test vs.
Normal (No) values.
doi:10.1371/journal.pone.0006078.g003
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experiments, we assessed the effects of TRA on ocular dominance
in animals not exposed to prior MD (NoMD+TRA cats, n=3). As
shown in Fig. S3A–D, while TRA has clear effects on the sleep/
wake architecture of these cats, it does not change scalar measures
of ocular dominance. In the second set of experiments, we assessed
the effects of acute administration of trazodone (vs. DMSO
vehicle) in a subset of recorded neurons. This was done by
recording a set of neurons (total n=39) over a baseline period, for
30 min following i.v. administration of vehicle, and for 30 min
following subsequent i.v. administration of trazodone, using
procedures comparable to those employed previously by other
investigators [2] and our own lab [3]. As shown in Fig. S3E, no
significant effects of either treatment were found on peak firing
rates, spontaneous firing rates, orientation selectivity, or visual
responsiveness for this set of neurons.
Discussion
Using a combination of polysomnography, in vivo single-unit
recording, and intrinsic signal imaging, we assessed the effects of
commonly-prescribed hypnotics on consolidation of ocular
dominance plasticity during sleep. We found that the ‘‘z’’
hypnotics ZAL and ESZ have profound effects on sleep EEG
activity, but only TRA - which antagonizes 5-HT2, H1, and a1-
adrenergic receptors - significantly interferes with sleep-dependent
consolidation of cortical plasticity.
TRA effects on sleep-dependent consolidation of ocular
dominance plasticity
We find that TRA impairs consolidation of cortical plasticity
during post-MD sleep when administered at 10 mg/kg - a dosage
roughly equivalent (on a mg/kg basis) to the highest clinical dose
typically given to patients for insomnia and/or depression [22,23].
In contrast, the dosages of ZAL and ESZ administered in this
study (also 10 mg/kg) represent the upper limit used in many
animal studies [24–26], and constitute between 30–100 times the
maximum prescribed dose for humans [23,27]. Thus the finding
that 10 mg/kg TRA impairs sleep-mediated ocular dominance
plasticity - while 10 mg/kg ZAL or ESZ do not significantly affect
it - strongly indicates that pathways targeted by TRA at clinically-
Figure 4. Trazodone impairs sleep-dependent changes in deprived eye and non-deprived eye responses. Cumulative distributions in A
show normalized peak firing responses of V1 neurons from each treatment group to preferred-orientation stimulation of the left eye (NDE) and right eye
(DE). Data from VEH and hypnotic-treated groups are compared to values from normally-sighted, untreated controls (Normal). All groups showed
significant augmentation of NDE firing response rates vs. Normal; responses from ZAL-treated animals showed further enhancement relative to VEH. In
contrast, NDE response augmentation was slightly (but not significantly) reduced in V1 of TRA-treated cats (p=0.09 vs. VEH). All groups also showed
significant depression of DE responses compared to responses in Normal V1; this depression was significantly inhibited in TRA-treated cats, and was
significantly enhanced in ZAL-treated cats (vs. VEH). Cumulative distributions in B show orientation selectivity indices (OSI45) for the two eyes, assessed
as described above. In all groups, NDE orientation selectivity was enhanced relative to that seen in Normal V1. NDE selectivity was further enhanced
(relative to VEH) in neurons from ESZ- or ZAL-treated cats, and slightly (but significantly) reduced in neurons from TRA-treated cats. All groups also
showed reduced DE orientation selectivity (relative to Normal V1). In all hypnotic-treated groups, DE selectivity was significantly less depressed than in
neurons from VEH-treated cats. * in red indicates p,0.05 vs. Normal, Kolmogorov-Smirnov [K-S] test. * in black indicates p,0.05 vs. VEH, K-S test.
doi:10.1371/journal.pone.0006078.g004
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relevant doses are specifically involved in cortical remodeling
during sleep.
It is unlikely that the effects of TRA on ocular dominance
plasticity are caused by non-specific effects of TRA on V1
neurons. First, while the elimination half-life of TRA in healthy
young subjects (,5–6 h [28]) is longer than that of ZAL (about 1 h
[29]), it is roughly equal to that of ESZ [27,30], and is unlikely to
be present at significant levels at the time of single-unit ocular
dominance assessments, which typically took place 14–18 h after
drug administration. Furthermore, prior studies examining the
effects of 5-HT or a1-adrenergic receptor antagonism (antagonist
properties associated with TRA) on response properties of V1
neurons reported no gross defects in visual processing [31–33]. We
also find that while the compounds under study had different
effects on plasticity, none of them grossly perturbed visual responses
in V1 neurons (e.g., OSI45, peak firing rate; Fig. 4). Intrinsic
signal angle and polar maps from TRA animals (Fig. S2) likewise
show normal orientation tuning and response magnitude. And
finally, we find no effects of TRA alone (without prior MD) on
ocular dominance or visual responsiveness (Fig. S3A–D), and no
acute effects of TRA administration on visual response properties
of V1 neurons (Fig. S3E). Thus, the most parsimonious
interpretation of our findings is that TRA directly interferes with
synaptic plasticity mechanisms active in V1 during post-MD sleep.
While TRA did lead to substantial reductions in post-MD REM
sleep (Fig. 1), this effect is unlikely to directly cause impairments in
ocular dominance plasticity for the following reasons. First, similar
reductions in REMwere seen in all three hypnotic-treated groups, yet
only TRA significantly impaired plasticity in V1. Indeed, a previous
study showed that ocular dominance plasticity consolidation is not
affected by administration of triazolam, although it caused a more
profound suppression of REM than any of the drugs used in the
current study [11]. Second, we have recently demonstrated that
selective (non-pharmacological) REM sleep deprivation following
MD does not impair consolidation of this plasticity [7]. Lastly, the
degree of V1 plasticity during sleep is positively correlated with post-
MD NREM - and not with REM - sleep [9].
It remains unclear, however, what aspects of NREM sleep are
critical for consolidation of cortical plasticity. Cortical slow waves
and spindle oscillations have been proposed as mediators of
mnemonic processes [34,35], as have cortical neurotransmission
and neuromodulator release during NREM sleep [7,36–39]. Our
current findings suggest that TRA interferes with sleep dependent
plasticity without affecting NREM cortical oscillations (Fig. 2). On
the other hand, restorative sleep is reported following administra-
tion of ‘‘z’’ hypnotics which, as shown here, perturb NREM EEG
activity [3,4]. We find that these profound changes in NREM
EEGs are not associated with inhibition of ocular dominance
plasticity (Fig. 2 and [11]). Together, the available data suggest
that other cellular mechanisms active during NREM sleep - but
not apparent at the level of the EEG - are critical for consolidating
cortical plasticity.
Precisely what these mechanisms are is difficult to determine
because TRA has many effects, including antagonism at 5-HT2A
and 5-HT2C, a1-adrenergic, and histamine H1 receptors. TRA
also inhibits T-type calcium channels and is a weak serotonin
reuptake inhibitor [14,15,40]. However, of these potential
mechanisms, 5-HT2 receptor antagonism appears to be the most
likely factor in our results. Selective intracortical blockade of 5-
HT2C receptors reduces ocular dominance plasticity [32], and 5-
HT2C receptors facilitate long-term synaptic potentiation and
depression (LTP and LTD) in developing V1 in vitro [41,42].
On the other hand, there is no evidence that histamine
influences ocular dominance plasticity, and while noradrenergic
signaling is critical for ocular dominance plasticity [43], its effects
are mediated specifically by b-adrenergic receptors [44]. T-type
calcium channels have been shown to influence ocular dominance
plasticity [45,46], but the affinity of TRA for these channels is
much lower than for 5-HT2 receptors. At the dosage employed in
our current studies (10 mg/kg, with a maximum effective
concentration of around 25 mM), TRA is likely to profoundly
antagonize 5-HT2 receptors but only modestly affect T-type
channels [40,47]. Lastly, selective serotonin reuptake inhibitors
(e.g., fluoxetine) augment consolidation of motor skill learning during
post-training sleep [38] and restore cortical plasticity in adult mice
to levels seen during the critical period [48]. Therefore, our results
are best explained by a blockade of 5-HT2C receptors during sleep
which impairs the normal strengthening and weakening of
synapses in V1.
Serotonin signaling during sleep and cortical plasticity
An activation of 5-HT2 receptors during sleep may seem counter-
intuitive because, relative to waking, cortical serotonin levels are
relatively low [49–51]). However, these concentrations may be
sufficient to activate 5-HT2C receptors, which have a relatively high
affinity for serotonin compared to other 5-HT receptors [52], and
which are maximally expressed in the visual cortex during the
critical period [53]. It is also possible that serotonin release in the
sleeping cortex can increase depending on prior waking experience.
For example, locus coeruleus activity and cortical noradrenaline
levels are specifically up-regulated during NREM sleep following
training on an olfactory learning task, in a manner consistent with a
role in memory consolidation [54,55]. It is possible that a similar
use-dependent activation of serotonergic pathways may also occur
during sleep. Therefore, while the results of systemic injections
should be cautiously interpreted, our findings suggest that blockade
of 5-HT2C receptors impairs the normal strengthening and
weakening of synapses in V1 during post-MD sleep.
A serotonergic mechanism may also explain why, of the ‘‘z’’
hypnotics examined here and in a prior study, only zolpidem
significantly reduces ocular dominance plasticity [11]. While this
difference may be partly explained by minor differences in these
drugs’ affinity for a1-, a5- or c3-containing GABAA receptors
[12,13] or their pharmacokinetics [30] - i.e., by slightly differing
GABAA receptor agonist properties - it more likely reflects the
known effects of zolpidem on cerebral serotonin signaling. At the
dose used in our prior study, zolpidem has been shown to reduce
cerebral serotonin accumulation [56] and enhance the suppression
of firing in serotonin-releasing median raphe neurons by GABAA
receptor agonists [57]. In contrast, there is no evidence that the
dosage of ZAL or ESZ used in our current experiment would have
the same effect [58].
Conclusions
The results of systemic drug treatment should be cautiously
interpreted for several reasons. The effects of systemic drug
treatments on central nervous system function may vary across
mammalian species (i.e. cats vs. humans); therefore complementary
studies in humans are required. In addition, our results do not
exclude the possibility that supra-clinical doses of the ‘‘z’’
hypnotics might also inhibit the consolidation of cortical plasticity,
or that alterations of monoaminergic signaling during wakefulness
might impair the induction of ocular dominance plasticity.
Nevertheless, our findings are important because they provide
new evidence suggesting that monoaminergic signaling during
sleep contributes to cortical plasticity. In addition, and in
agreement with an earlier report [11], they demonstrate that
hypnotics producing major alterations in sleep architecture do not
Hypnotics, Sleep & Plasticity
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necessarily impair neural functions of sleep. Conversely, agents
that produce more ‘‘physiological’’ sleep based on polysomno-
graphy - such as TRA - may grossly impair these functions.
Our results may also have important clinical implications. TRA
is commonly prescribed to pediatric patients - not only for
insomnia [59] and mood disorders [60,61], but also for migraine
prophylaxis [62] and treatment of behavior disorders (such as tic
disorders [63], aggressive behavior disorders [64], and attention
disorders [65]). Thus our current findings raise important
questions regarding the consequences of long-term use of these
drugs in pediatric populations.
Materials and Methods
Experimental design and formation of groups
Animals were housed and treated in accordance with University
of Pennsylvania IACUC regulations for animal care and use. All
invasive procedures were performed under anesthesia and survival
procedures were accompanied with pre- and post-operative care as
described previously [8,9]. We used an experimental design similar
to that used previously to test the effects of benzodiazepine and
non-benzodiazepine hypnotics on sleep-dependent ocular domi-
nance plasticity [11](Fig. 1A). At postnatal days P24–28, cats were
randomly assigned to control (vehicle [VEH], n=6; data from 4
cats reproduced with permission from Seibt et al. [11]) or
experimental groups. Experimental groups were treated with
either zaleplon (ZAL, n=5), eszopiclone (ESZ, n=6), or trazodone
(TRA, n=5), as described below (Drug treatments). Whenever
possible, siblings were distributed evenly across different groups to
minimize potential litter effects. In addition, a group of animals
with unmanipulated, binocular vision and unmanipulated sleep
(Normal, n=7) was used for comparison of ocular dominance
measures with the main treatment groups. Four of the Normal cats
were previously used to provide normative data in an earlier study
(reproduced with permission from Jha et al. [8]). There was no
difference in age between any of the groups (F=0.93, p=0.46,
one-way ANOVA). Circadian factors are unlikely to play a role in
sleep-dependent ocular dominance plasticity because circadian
rhythms in sleep/wake and other parameters are extremely weak
in cats [66–68] and entirely absent in critical period kittens [69].
Nevertheless, all experimental manipulations were done at the
same time of day.
Surgical procedures and sleep/wake recording
All cats in VEH and hypnotic treatment groups were implanted
with EEG/EMG electrodes on postnatal days P21–28 as described
previously [11]. Briefly, five EEG electrodes were placed
bilaterally in frontal and parietal bones of the skull (1–2 cm away
from V1), and three EMG electrodes (braided stainless-steel wire)
were placed deep into the nuchal muscle. Electrodes were
connected to an electrical socket fixed to the skull with bone
screws and dental acrylic. After 4–5 d of postoperative recovery,
cats were placed in a light proof, illuminated sleep-recording
chamber with a revolving base. EEG/EMG signals were
continuously recorded during a 6-h baseline period, a 6-h
monocular deprivation (MD) period, and a 6-h post-MD sleep
period in total darkness (Fig. 1A). Cats were provided with food
and water ad lib at all times. Polygraphic signals were amplified
with an Astro-Med (West Warwick, RI) amplifier system, filtered
(high-pass at 0.3 Hz, low-pass at 100 Hz), digitized at 200 Hz, and
recorded as previously described using SleepSign software (Kissei
Comtec; Irvine, CA)[8].
Following the baseline recording period, cats were anesthetized
with isoflurane and had their right eyelids sutured closed as
previously described [9]. Following recovery, cats were returned to
their recording chambers and were kept awake (through a
combination of gentle handling, novel object exploration,
vocalization, and floor rotation) under normal room illumination
for the next 6 h to provide a common stimulus for remodeling in
V1 [8,9]. The deprived eye remained sutured closed in all cases
until the time of acute ocular dominance assessments.
Sleep/wake analysis
EEG and EMG signals were used to assign polygraphic data
into 8-s epochs of non-REM sleep (NREM), REM sleep, and
waking states using SleepSign software. The proportion of time
spent in REM, NREM, and waking (and mean bout duration for
each state) was calculated separately for baseline, MD, and post-
MD sleep periods using standard conventions. Fast-Fourier
transforms (FFT; SleepSign) were used to assess EEG spectra
between 0–40 Hz in each sleep state as described previously [11].
EEG power in each frequency band during post-MD sleep was
normalized for each cat as a percentage of the pre-MD baseline.
As described in the RESULTS section, we also observed an
apparent intermediate state between waking and NREM sleep -
described as ‘‘NREM-drowsy’’ (ND) - in a subset of ESZ- and
ZAL-treated animals (n=2 and n=1, respectively). However, the
amount of ND in these animals was very low across the 8-h post-
MD sleep period (0.7%60.4% and 2.1% of total recording time,
respectively; data not shown). As described in a prior study [11],
this sleep stage was analyzed separately for EEG power spectra but
included in the sleep bout calculations as NREM because of its
behavioral and EEG similarities to NREM sleep.
Drug treatments
All drugs (and vehicle) were administered in a single i.p.
injection which was given immediately following the 6-h period of
waking MD, at the beginning of the post-MD sleep period
(Fig. 1A). Zaleplon (ZAL; Sepracor; Marlborough, MA) and
trazodone (TRA; Sigma; St. Louis, MO) were diluted in 0.25–
0.75 ml of DMSO vehicle and administered at 10 mg/kg.
Eszopiclone (ESZ; Sepracor) was diluted in 0.25–0.75 ml of an
aqueous acetate buffer vehicle solution containing 28 mM glacial
acetate and 221 mM sodium acetate trihydrate (pH 4.5), and
delivered at a dosage of 1 mg/kg (n=2 cats) or 10 mg/kg (n=4
cats). Preliminary findings indicated that the low and high dosages
of ESZ had similar effects on sleep and ocular dominance
plasticity, and that neither of the two drug vehicles used as controls
(DMSO, n=5, or acetate buffer, n=1) had substantial effects on
sleep or ocular dominance plasticity. Thus, for simplicity, data
from these animals were grouped together, in ESZ and VEH
treatment groups, respectively.
Single-unit electrophysiology and ocular dominance
analysis
To assess ocular dominance and right eye/DE and left eye/
NDE response properties, micro-electrode recordings of single
neurons were performed in all groups as described previously [8].
Contact lenses were placed in the eyes (for optimum focus to a
monitor positioned at a distance of 40 cm), and neuronal
responses to grating stimuli presented to either eye were recorded
using a 161 mm array of 16 electrodes (Frederick Haer;
Bowdoinham, ME) which was placed within V1, as described
previously [9]. Depth of recording (measured in 100 mM steps
from the pial surface, as described previously [7]) was similar
between neurons recorded from all hypnotic-treated groups and
those recorded from VEH cats (N.S., Dunn’s post hoc test; median
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depth of recording sites [25th, 75th percentile] for these groups
were: VEH: 300 mM [200, 400 mM], ZAL: 200 mM [200,
400 mM], ESZ: 300 mM [200, 400 mM], TRA: 300 mM [200,
300 mM]). The number of neurons recorded from each animal
also did not differ between groups (N.S., one-way ANOVA; mean
number of neurons recorded from these groups [6SEM] were:
VEH: 115612, ZAL: 131613, ESZ: 129615, TRA: 121613).
Thus there was no systematic bias in the distribution of recordings
from the various groups across cortical layers. For each set of
neurons recorded, eight full-field, slowly-drifting, reversing
gratings (0.2 cycles/degree, 5-s presentation) were presented
randomly to each eye four times (468 different orientations at
22.5u intervals+blank screen per eye).
Single-unit data was discriminated offline (Offline Sorter;
Plexon, Inc.; Dallas, TX) and mean firing rates in each neuron
were assessed for each eye and stimulus presentation as described
previously [8]. Left eye/right eye response ratios were computed
at the preferred orientation and ranked on a conventional 7-point
ocular dominance scale using a computer algorithm that
approximates subjective scoring rules [8]. Previously used and
accepted scalar measures of ocular dominance were then used to
quantify the single-unit distributions in each hemisphere [8,9]. To
simplify our presentation, the traditional contralateral bias index
(CBI) was modified so that scores of 1 indicated complete
dominance by the non-deprived eye, 0 complete deprived eye
dominance and 0.5 equal representation of both eye in the
hemisphere under study (a metric hereafter referred to as the
‘‘non-deprived eye bias index’’: NBI). We also calculated
monocularity indices (MI) for each hemisphere and for com-
bined-hemisphere data, and shift indices (SI) as previously
described [8,9]. An MI value of 1 indicates a complete loss of
binocular responses and 0 indicates that all neurons respond
equally to stimuli presented to either eye. The shift index (SI)
measures overall changes in ocular dominance across both
hemispheres (CBIIpsilateral to the DE- CBIcontralateral to the DE) with
a value of 0 indicating complete binocularity, and 1 or -1
indicating complete shifts toward one eye or the other [9,70].
Visual response properties
Several additional single-unit response properties were mea-
sured using previously published and established procedures [7].
For calculations of peak firing (at each neuron’s preferred
orientation) and to blank screen (a measure of spontaneous
activity), firing rates were normalized to the mean firing rate of
neurons recorded across the electrode array at a given recording
position (across all stimulus presentations). This normalization,
which is comparable to normalizations used elsewhere [71],
corrected for normal fluctuations in anesthetic depth between
measurements and inter-animal variability within a group.
Orientation selectivity was calculated using the previously
described orientation selectivity indices [18]. Briefly, mean firing
rates were computed at each neuron’s preferred stimulus
orientation and the oblique (45u from preferred; OSI45) and
orthogonal (90u from preferred; OSI90) orientation. Ratios of unit
firing rates were calculated (response at oblique/preferred or
orthogonal/preferred for OSI45 and OSI90, respectively) and
subtracted from 1. Indices of 1 indicate a high degree of selectivity,
and indices of 0 indicate a lack of selectivity. Because vehicle and
hypnotic treatments similarly affected DE and NDE OSI45 and
OSI90 values, OSI45 distributions only are shown for simplicity.
Distributions of these response parameters were statistically
evaluated for DE and NDE responses as described by others
[19,72]. For display purposes (e.g., in Fig. 4) a running average
smoothing function (sampling proportion = 0.1; SigmaPlot; Systat
Software, Inc.; San Jose, CA) was used in the cumulative
histogram figures, but statistics were always performed on
unsmoothed data.
Statistics
All values are expressed as means6SEM as indicated. Statistical
analyses were performed using SigmaStat software (Systat
Software Inc.; San Jose, CA). All data were first tested for
normality and skew. Parametric data were assessed using one- or
two-way ANOVA and post hoc Holm-Sidak tests (SigmaStat
software; Systat Software Inc.; San Jose, CA); in cases where
non-parametric statistics were required, Kruskal Wallis ANOVA
and Dunn’s tests were used. Cumulative distributions of values for
single-unit response properties (OSI, firing rates) were compared
using Kolmogorov-Smirnov (K-S) tests as previously described
[19,72] (Matlab software; The Mathworks, Inc.; Natick, MA).
Mean percentages and mean bout durations of sleep/wake data
were either compared for the entire 8-h post-MD period (Fig. 1),
or were analyzed using two-way repeated measures ANOVA to
test for effects of drugs over time (Fig. S1, Table S1). EEG power
spectra were compared separately in each 2-h bin in the post-MD
period using two-way ANOVA (group and frequency as main
factors).
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